Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrian Wiestner

Showing results (121-130 of 149) with videos related to

Pageof 15
Sort By:
Blood|January 5, 2017
Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemiaInhye E Ahn, Chingiz Underbayev, Adam Albitar, et al.
Nature|February 16, 2017
Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cellsMara Compagno, Qi Wang, Chiara Pighi, et al.
Blood|February 22, 2003
ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profileAdrian Wiestner, Andreas Rosenwald, Todd S Barry, et al.
Blood|April 30, 2010
Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphomaVioletta V Leshchenko, Pei-Yu Kuo, Rita Shaknovich, et al.
Blood|October 20, 2010
Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiationPatricia Pérez-Galán, Helena Mora-Jensen, Marc A Weniger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 2, 2016
The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic LeukemiaSarah E M Herman, Arnau Montraveta, Carsten U Niemann, et al.
Blood|March 24, 2020
Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinibClare Sun, Pia Nierman, Ellen K Kendall, et al.
Nature Communications|December 21, 2017
The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapyDan A Landau, Clare Sun, Daniel Rosebrock, et al.
Leukemia|January 12, 2017
Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral bloodThomas M Herndon, Shih-Shih Chen, Nakhle S Saba, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 15, 2015
Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II StudyCarsten U Niemann, Sarah E M Herman, Irina Maric, et al.
Pageof 15

Showing results (121-130 of 149) with videos related to

Sort By:
Pageof 15
Blood|January 5, 2017
Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemiaInhye E Ahn, Chingiz Underbayev, Adam Albitar, et al.
Nature|February 16, 2017
Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cellsMara Compagno, Qi Wang, Chiara Pighi, et al.
Blood|February 22, 2003
ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profileAdrian Wiestner, Andreas Rosenwald, Todd S Barry, et al.
Blood|April 30, 2010
Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphomaVioletta V Leshchenko, Pei-Yu Kuo, Rita Shaknovich, et al.
Blood|October 20, 2010
Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiationPatricia Pérez-Galán, Helena Mora-Jensen, Marc A Weniger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 2, 2016
The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic LeukemiaSarah E M Herman, Arnau Montraveta, Carsten U Niemann, et al.
Blood|March 24, 2020
Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinibClare Sun, Pia Nierman, Ellen K Kendall, et al.
Nature Communications|December 21, 2017
The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapyDan A Landau, Clare Sun, Daniel Rosebrock, et al.
Leukemia|January 12, 2017
Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral bloodThomas M Herndon, Shih-Shih Chen, Nakhle S Saba, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 15, 2015
Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II StudyCarsten U Niemann, Sarah E M Herman, Irina Maric, et al.
Pageof 15